ARTICLE | Company News
OxiGene, Bristol-Myers deal
July 1, 2002 7:00 AM UTC
OXGN received worldwide rights from BMY to IP covering a formulation of OXGN's Combretastatin A4 Prodrug ( CA4P), a phosphatase activated tumor vascular targeting agent that has completed Phase I clin...